EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Synthetic CB1 Modulators in Clinical Trials: A Medicinal Chemistry Review

Gustavo Manoel Oliveira Dos Santos Naziozene, Roberto Parise-Filho iD

ChemMedChem · 15.06.2026 · 21 (11)

DOI: 10.1002/cmdc.70302 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 31.05.2026. Verfasst von Gustavo Manoel Oliveira Dos Santos Naziozene und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 136 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The endocannabinoid system, comprising CB1 and CB2 receptors, endogenous ligands, and metabolic enzymes, regulates appetite, energy balance, nausea, immune responses, and neuroprotection. Despite its therapeutic potential, clinical translation has been limited, with only dronabinol and nabilone approved since the 1980s, largely due to central adverse effects associated with CB1 modulation. This review examines synthetic small‐molecule CB1 modulators that have advanced to clinical trials from a medicinal chemistry perspective. Nine compounds (five agonists and four antagonists) were identified for indications including autism spectrum disorder, neuropathic pain, osteoarthritis, obesity, acute cannabinoid intoxication, and cognitive impairment in Down syndrome. A comparative structure–activity relationship analysis encompassing 189 molecules revealed recurrent design strategies across different chemical classes, particularly modifications in homologous regions such as lateral chains and tail domains. While agonists generally exhibited limited selectivity between CB1 and CB2 receptors, antagonists more readily achieved CB1 selectivity. Central nervous system adverse effects remain the principal challenge, driving the development of peripherally restricted ligands, biased modulators, and compounds with improved metabolic profiles. Collectively, the insights discussed herein highlight how the integration of structural, pharmacological, and clinical data can guide the rational design of safer and more effective CB1 receptor modulators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB1HumansStructure-Activity RelationshipClinical Trials as TopicChemistry, PharmaceuticalAnimalsMolecular Structure

Stichwörter der Autor:innen

CB1 modulationendocannabinoid systemstructure–activity relationship (SAR)synthetic cannabinoids

Substanzen

Receptor, Cannabinoid, CB1

Autor:innen und Institutionen

  • Department of Pharmacy, University of São Paulo, São Paulo, Brazil.

ORCID-Profile: Roberto Parise-Filho

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • FAPESP

Zitieren

APA

Dos Santos Naziozene, G. M. O., & Parise-Filho, R. (2026). Synthetic CB1 Modulators in Clinical Trials: A Medicinal Chemistry Review. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70302

Vancouver

Dos Santos Naziozene GMO, Parise-Filho R. Synthetic CB1 Modulators in Clinical Trials: A Medicinal Chemistry Review. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70302

BibTeX
@article{DosSantosNaziozene2026,
  author = {Dos Santos Naziozene, Gustavo Manoel Oliveira and Parise-Filho, Roberto},
  title = {Synthetic CB1 Modulators in Clinical Trials: A Medicinal Chemistry Review},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {11},
  doi = {10.1002/cmdc.70302}
}
Kostenlos starten →